FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

The FDA has accepted Insmed's supplemental new drug application for Arikayce to treat newly diagnosed MAC lung disease patients and granted priority review with a decision date of January 28, 2027. The label expansion would increase Arikayce's addressable patient population from 30,000 to more than 200,000.

INSM reported Arikayce sales of $214.4 million in the first half of 2026, up 7% year-over-year. The company projects full-year 2026 sales between $450 million and $470 million for the product.

Arikayce is currently approved for refractory MAC lung disease. The pending expansion would allow treatment of newly diagnosed patients, capturing a significantly larger market segment at the start of the care pathway rather than only after other therapies fail.

The January 2027 PDUFA date creates a binary event for INSM shares. A positive decision would unlock immediate commercial opportunity in a market more than six times larger than the current label.